US EditionScientists at The Wistar Institute and Stanford University Report Encouraging Results on First-in-Human Clinical Trial for an Investigational Drug to Treat Epstein-Barr Virus Cancer
Summary by wistar.org
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Scientists at The Wistar Institute and Stanford University Report Encouraging Results on First-in-Human Clinical Trial for an Investigational Drug to Treat Epstein-Barr Virus Cancer
PRESS RELEASE CONTACT: Darien Sutton 215-898-3988 | dsutton@wistar.org PHILADELPHIA — (January 20, 2025) — In newly reported clinical trial results, The Wistar Institute and Stanford University have successfully tested an investigational drug for the treatment of Epstein-Barr Virus (EBV)-positive nasopharyngeal cancer (NPC) in humans. The drug VK-2019 was tested in a first-in-human clinical trial by a research team led by Wistar research a…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
